Hepatic steatosis provides the terroir that promotes the development of cardiovascular risk factors and disease
- 6 February 2023
- journal article
- editorial
- Published by Wolters Kluwer Health in Hepatology
- Vol. 77 (6) , 1843-1845
Abstract
No abstract availableThis publication has 10 references indexed in Scilit:
- The association between hepatic steatosis and incident cardiovascular disease, cancer, and all-cause mortality in a US multicohort studyHepatology, 2023
- Clinical course of non-alcoholic fatty liver disease and the implications for clinical trial designJournal of Hepatology, 2022
- An approach to quantifying the potential importance of residual confounding in systematic reviews of observational studies: A GRADE concept paperEnvironment International, 2021
- Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: an updated systematic review and meta-analysisThe Lancet Gastroenterology & Hepatology, 2021
- Using the E-Value to Assess the Potential Effect of Unmeasured Confounding in Observational StudiesJAMA, 2019
- Nonalcoholic fatty liver disease incidence and impact on metabolic burden and death: A 20 year‐community studyHepatology, 2017
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2016
- Body Mass Index and Risk of Nonalcoholic Fatty Liver Disease: Two Electronic Health Record Prospective StudiesThe Journal of Clinical Endocrinology & Metabolism, 2016
- Separate and combined associations of body-mass index and abdominal adiposity with cardiovascular disease: collaborative analysis of 58 prospective studiesThe Lancet, 2011
- Cardiovascular events in type 2 diabetes: comparison with nondiabetic individuals without and with prior cardiovascular disease 10-year follow-up of the Hoorn StudyEuropean Heart Journal, 2003